Orchid Pharma reported a standalone net profit of ₹12 crore for the first quarter of FY27, reversing the net loss of ₹3 crore recorded in the corresponding period of the previous fiscal year. This shift from loss to profit highlights an improvement in the company's bottom-line performance amidst top-line growth.

Revenue from operations stood at ₹304 crore, up from ₹263 crore in the same quarter last year, representing a 16% increase. The rise in revenue coincided with a significant expansion in operating margins, suggesting improved operational efficiency and cost management during the period following the strategic amalgamation with Dhanuka Laboratories Ltd., which became effective on July 10, 2026.

Financial Performance

The company’s ability to generate profit while growing revenue indicates a positive trend in its financial health. The reversal of losses to profits is a key indicator of stabilized operations within the integrated platform.

What the Numbers Show

The simultaneous rise in revenue and the transition from a net loss to a net profit suggests that Orchid Pharma has effectively managed its cost structure relative to its sales growth. The revenue increase of 16% coupled with a 178% surge in EBITDA underscores a period of financial recovery. Notably, the EBITDA margin expanded from 3% to 8%, indicating that operating leverage is improving as the merged entity optimizes its integrated cephalosporin platform spanning key starting materials to finished dosage forms.

Orchid Pharma has scheduled its quarterly earnings call to discuss financial results for the period ended June 30, 2026. The conference call is set for Friday, August 21, 2026, at 3:00 pm IST and will be hosted by Systematix Institutional Equities.

The event aims to provide investors with insights into the company's operational and financial performance for the first quarter of the fiscal year. Participants can access the call via dial-in numbers provided for India, the USA, the UK, Singapore, and Hong Kong.

Management Participation

Key executives from Orchid Pharma will represent the company during the session. The management lineup includes:

• Manish Dhanuka, Managing Director
• Mridul Dhanuka, Whole Time Director
• Sunil Kumar Gupta, Chief Financial Officer

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also references SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kapil Dayya, Company Secretary and Compliance Officer, signed the disclosure. The information is available on the company's website at www.orchidpharma.com .

Dial-In Details

Investors and analysts can join the conference call using the following numbers:

A Diamond Pass service is available for premium access without operator wait times. For further inquiries, participants may contact Vishal Manchanda or Mrunal Pawar at Systematix Group.